Treatment of malignant tumors of the skull base with multi-session radiosurgery

• Published in: Journal of hematology and oncology Vol. 2; no. 1; p. 16
• Main Authors: Coppa, Nicholas D, Raper, Daniel M S, Zhang, Ying, Collins, Brian T, Harter, K William, Gagnon, Gregory J, Collins, Sean P, Jean, Walter C
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.04.2009; BioMed Central; BMC
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell - surgery; Child; Female; Hemangiopericytoma - surgery; Humans; Male; Middle Aged; Periodicity; Radiation Dosage; Radiosurgery - adverse effects; Radiosurgery - methods; Retrospective Studies; Skull Base Neoplasms - surgery; Surgery, Computer-Assisted - methods; Young Adult
• ISSN: 1756-8722; 1756-8722
• DOI: 10.1186/1756-8722-2-16

Malignant tumors that involve the skull base pose significant challenges to the clinician because of the proximity of critical neurovascular structures and limited effectiveness of surgical resection without major morbidity. The purpose of this study was to evaluate the efficacy and safety of multi-session radiosurgery in patients with malignancies of the skull base. Clinical and radiographic data for 37 patients treated with image-guided, multi-session radiosurgery between January 2002 and December 2007 were reviewed retrospectively. Lesions were classified according to involvement with the bones of the base of the skull and proximity to the cranial nerves. Our cohort consisted of 37 patients. Six patients with follow-up periods less than four weeks were eliminated from statistical consideration, thus leaving the data from 31 patients to be analyzed. The median follow-up was 37 weeks. Ten patients (32%) were alive at the end of the follow-up period. At last follow-up, or the time of death from systemic disease, tumor regression or stable local disease was observed in 23 lesions, representing an overall tumor control rate of 74%. For the remainder of lesions, the median time to progression was 24 weeks. The median progression-free survival was 230 weeks. The median overall survival was 39 weeks. In the absence of tumor progression, there were no cranial nerve, brainstem or vascular complications referable specifically to CyberKnife radiosurgery. Our experience suggests that multi-session radiosurgery for the treatment of malignant skull base tumors is comparable to other radiosurgical techniques in progression-free survival, local tumor control, and adverse effects.